CRDL Overview

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Cardiol Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased

Cardiol Therapeutics Inc. EPS for the last quarter amounts to -0.10 USD, decreased -0.00

Cardiol Therapeutics Inc (CRDL) has 18 emplpoyees as of July 08 2026.

Today CRDL has the market capitalization of 116.42M USD.